Data Sheet (Cat.No.T17209)

TargetMol

UVI 3003

Chemical Properties



CAS No. : 847239-17-2

Formula: C28H36O4

Molecular Weight: 436.58

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	UVI 3003 is a highly selective antagonist of the retinoid X receptor, inhibiting Xenopus and human RXRα in Cos7 cells with IC50 values of 0.22 μM and 0.24 μM, respectively.
Targets(IC50)	Retinoid Receptor,Autophagy
In vitro	UVI3003 fully activates xPPARγ (EC50: 12.6 μM) and is almost completely inactive on hPPARγ and mPPARγ. UVI 3003 causes a 65.4% difference in EECD34 cell fusion and desmin expression. UVI 3003 (10 μM) does not change the proliferation rate of extraocular muscles (EOM)-derived or LEG-derived EECD34 cells [1][2].

Solubility Information

Solubility	DMSO: 150 mg/mL (343.58 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (22.91 mM),Solution. 10% DMSO+90% Saline: < 10 mg/mL (22.91 mM),Lower concentrations may be soluble, but exact solubility limit is unknown. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2905 mL	11.4527 mL	22.9053 mL
5 mM	0.4581 mL	2.2905 mL	4.5811 mL
10 mM	0.2291 mL	1.1453 mL	2.2905 mL
50 mM	0.0458 mL	0.2291 mL	0.4581 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Zhu J, et al. The unexpected teratogenicity of RXR antagonist UVI3003 via activation of PPARγ in Xenopus tropicalis. Toxicol Appl Pharmacol. 2017 Jan 1;314:91-97.

Hebert SL, et al. Effects of retinoic acid signaling on extraocular muscle myogenic precursor cells in vitro. Exp Cell Res. 2017 Dec 1;361(1):101-111.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481